Zhang Yi, Cheng Brian Chi-Yan, Li Cui, Tao Yonghua, Yu Chanjuan, Liu Xinyue, Gao Xiaoyan, Luo Gan
School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 100102 China.
College of Professional and Continuing Education, Hong Kong Polytechnic University Hong Kong 999077 China.
RSC Adv. 2019 Sep 25;9(52):30292-30301. doi: 10.1039/c9ra06177k. eCollection 2019 Sep 23.
Inhalation therapy is the first-line therapy for the treatment of respiratory diseases. inhalation solution (RIS) is an aerosol derivative from the injection and has been clinically used to treat respiratory diseases like pneumonia for more than twenty years in China. However, the aerosolization and inhalation performances of RIS using different nebulizers have not been characterized, which may affect the therapeutic effects of RIS on respiratory diseases. We investigated the inhalation performances of RIS using five different nebulizers utilizing Spraytec, breath simulator of BRS 2000 and NGI techniques. We tested 5 different types of jet nebulizer, using RIS and an adult breathing pattern, to determine the difference in aerosol delivery over time. The particle size distribution of RIS was monitored by a Spraytec laser particle sizer. Fine particle fraction (FPF) and mass median aerodynamic diameter (MMAD) for RIS were measured using NGI. Aerosol deposited on the filter was analysed using HPLC. Nebulization time was much longer for the Pari Boy SX (red) nebulizer than for the other nebulizers, with the minimum delivery rate (DR) and the maximum total delivered dose (TDD) and total exhalation dose (TED). Nebulization time for Pari Boy SX (blue) was the lowest, with the highest DR and the lowest TDD and TED. Furthermore, the aerodynamic particle size of RIS was much larger for the Pari blue and Pari LC Plus than other nebulizers. Pari red produced the smallest aerodynamic particle size of RIS in these five nebulizers. In addition, a good linear relationship was found between MMAD and in these five nebulizers. The results demonstrated that Pari Boy SX (red) delivered most slowly and produced the smallest aerodynamic particle size of the RIS aerosols, which may be applied to manage lower respiratory diseases. Moreover, Pari LC Plus and Pari Boy SX (blue) emitted quickly and generated larger aerodynamic particle size of RIS aerosols, which could be used to treat upper respiratory diseases. A good linear relationship between MMAD and showed Spraytec could be a reliable technique for the development, evaluation and quality control of aerosol particles of inhalation solution preparations.
吸入疗法是治疗呼吸系统疾病的一线疗法。吸入溶液(RIS)是一种由注射剂衍生而来的气雾剂,在中国已临床用于治疗肺炎等呼吸系统疾病二十多年。然而,使用不同雾化器时RIS的雾化和吸入性能尚未得到表征,这可能会影响RIS对呼吸系统疾病的治疗效果。我们利用Spraytec、BRS 2000呼吸模拟器和NGI技术研究了使用五种不同雾化器时RIS的吸入性能。我们使用RIS和成人呼吸模式测试了5种不同类型的喷射雾化器,以确定随时间的气溶胶递送差异。通过Spraytec激光粒度仪监测RIS的粒度分布。使用NGI测量RIS的细颗粒分数(FPF)和质量中值空气动力学直径(MMAD)。使用高效液相色谱法分析沉积在过滤器上的气溶胶。Pari Boy SX(红色)雾化器的雾化时间比其他雾化器长得多,其最小递送率(DR)、最大总递送剂量(TDD)和总呼气剂量(TED)。Pari Boy SX(蓝色)的雾化时间最短,DR最高,TDD和TED最低。此外,Pari蓝色和Pari LC Plus的RIS空气动力学粒径比其他雾化器大得多。在这五种雾化器中,Pari红色产生的RIS空气动力学粒径最小。此外,在这五种雾化器中,MMAD与 之间发现了良好的线性关系。结果表明,Pari Boy SX(红色)递送最慢,产生的RIS气溶胶空气动力学粒径最小,可用于治疗下呼吸道疾病。此外,Pari LC Plus和Pari Boy SX(蓝色)发射迅速,产生的RIS气溶胶空气动力学粒径较大,可用于治疗上呼吸道疾病。MMAD与 之间的良好线性关系表明,Spraytec可能是吸入溶液制剂气溶胶颗粒开发、评估和质量控制的可靠技术。